Navigation Links
Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting
Date:5/15/2008

a experienced a 20 percent tumor reduction. Lastly, a patient with NK/T cell lymphoma had a 75 percent reduction in tumor measurements. Adverse events included two Grade 3 dose- limiting toxicities (upper respiratory infection (URI) and elevated liver enzymes) and five cases of Grade 3 thrombocytopenia (low-platelet count) without any sign of bleeding.

Reductions in platelet counts were analyzed in the three ongoing Phase I trials as a biomarker of Bcl-2 family protein inhibition. Subjects received doses ranging from 10 mg to 315 mg. The study data demonstrate that ABT-263 induces a transient decrease in circulating platelets via inhibition of Bcl- XL, without decreasing platelet production, confirming on-target activity. At 315 mg, researchers observed a 69 percent reduction in mean platelets from baseline values. Typically, platelet nadir occurred on days three to five with recovery during continued dosing. Tumor regression was observed in six patients, with three patients showing more than 50 percent tumor shrinkage. Adverse events included three dose-limiting toxicities, one Grade 3 URI at 160 mg, one Grade 3 alanine aminotransferase (ALT) elevation at 315 mg and one fatal respiratory failure at 10 mg. Updated information will be presented at the ASCO Annual Meeting.

ABT-869

Twenty-four patients from a completed Phase I trial (ABT-869), which studied three dose levels of ABT-869, were evaluated to compare two different measures of angiogenesis using functional imaging -- the distributed parameter (DP) model and the transfer constant (Ktrans) model. DP is a dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) model that enables derivation of blood flow and capillary permeability-surface area product (PS). Tests indicated that time over threshold could be an important predictor of efficacy, and results demonstrated that an appropriate value for the plasma concentration threshold could be 0.08 ug/mL, with time above threshold value of
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Abbott to Present at Citi Investment Research Global Health Care Conference
2. Abbott to Present at Morgan Stanley Global Healthcare Unplugged Conference
3. Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
4. Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook
5. Innovative Diagnostic Instrument Introduced by Abbott for Low- to Mid-Volume Laboratory Market Segment
6. Abbott FreeStyle Freedom(R) Lite Blood Glucose Monitoring System Now Available With No Coding for People With Diabetes
7. Abbott Hosts Conference Call for First-Quarter Earnings
8. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
9. FDA Approves Abbotts FreeStyle Navigator(R) Continuous Glucose Monitoring System
10. Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent
11. Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... (PRWEB) August 01, 2014 The European gas ... Europe with analysis and forecast of revenue. The gas chromatography ... 2013, and is estimated to grow to around $247.6 million ... 2018. , Browse through the TOC of the European gas ... analysis provided. This also provides a glimpse of the segmentation ...
(Date:8/1/2014)... August 01, 2014 Recently, Agebc.com, a renowned ... of prom dresses . As a matter of fact, ... top experts. Aside from that, all of them are offered ... has a huge selection of graceful products for clients who ... sale will not last for a long period of time. ...
(Date:8/1/2014)... (GSA) the nation,s largest interdisciplinary organization devoted to ... Curran, PhD, of the University of Southern California as ... Award. , This distinguished honor is given for outstanding ... research. It was established in 1986 to honor Nathan ... in gerontological research at the National Institutes of Health. ...
(Date:8/1/2014)... Lifeinsurancenomedicalexam.info has released a new ... clients who have high cholesterol levels. , Clients ... qualify for no medical exam life insurance. These plans ... medical check-ups. , Since there are no medical examinations ... qualify in just a few minutes. However, this convenience ...
(Date:8/1/2014)... 01, 2014 Frontier Nursing University has ... Services Administration’s Advanced Education Nursing Traineeship (AENT) program ... direct support to 280 students over the grant period. ... is to increase the number of advanced education nurses ... faculty to address the nurse faculty shortage that inhibits ...
Breaking Medicine News(10 mins):Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Cheap Prom Dresses At The Renowned Dresses Manufacturer and Retailer Agebc.com 2Health News:Curran to receive GSA's 2014 Nathan Shock New Investigator Award 2Health News:No Exam Life Insurance - Coverage for Clients Who Have High Cholesterol 2Health News:Frontier Nursing University Receives $700,000 in Scholarships for Advanced Practice Nursing and Midwifery Students 2
... a new, targeted therapy for metastatic urothelial cancer has ... 35th Congress of the European Society for Medical Oncology ... tissue lining the inner surfaces of the bladder and ... metastatic disease, median survival is approximately 12-15 months and ...
... diagnosed with bone cancer could benefit from better treatment in ... Nottingham. The Bone Cancer Research Trust launches Bone Cancer ... the University which is testing a theory that ,friendly bacteria, ... at the School of Clinical Sciences, Division of Pre-Clinical Oncology ...
... cardiovascular surgeons and cardiologists from 25 countries are scheduled ... two-day surgical congress focused on the Ross Procedure. ... will feature the presentation of much new data about ... the world,s elite cardiovascular surgeons and cardiologists regarding survival, ...
... By Amanda Gardner HealthDay Reporter , MONDAY, ... be at higher risk for stroke even if they don,t ... attention to people who show signs of insulin resistance -- ... clear glucose from the bloodstream -- may be helpful in ...
... cancer can lead some people to wonder if their risk ... than 85,000 postmenopausal women observed that regular physical activity, maintaining ... risk for women with, and without a family history of ... published online Oct. 12, 2010, by the journal Breast ...
... artery that supplies blood to the brain, carotid artery ... an increased risk of both short- and long-term adverse ... to a meta-analysis of previously published studies that was ... 2011 print issue of Archives of Neurology , ...
Cached Medicine News:Health News:Pazopanib shows promise in Phase II trial for relapsed/refractory urothelial cancer 2Health News:Hope for a new treatment for bone cancer 2Health News:The Ross Summit to focus on new survival data, technique refinement and availability 2Health News:Insulin Resistance Might Raise Risk of Stroke 2Health News:Insulin Resistance Might Raise Risk of Stroke 3Health News:Breast-healthy lifestyle worthwhile, URMC study confirms 2Health News:Carotid stents associated with greater risk of stroke or death than carotid endarterectomy surgery 2Health News:Carotid stents associated with greater risk of stroke or death than carotid endarterectomy surgery 3
(Date:7/31/2014)... Indien, August 1, 2014 ... Inc. gaben heute bekannt, vor kurzem für ... zur Schmerzbehandlung nach chirurgischen Eingriffen eine kommerzielle ... der Europäischen Union und weiterer europäischer Länder ... und mit Ropivacain gefüllte OneDose ReadyfusOR später ...
(Date:7/31/2014)... 2014 STAAR Surgical Company (NASDAQ: ... implantable lenses and delivery systems for the eye today ... 2014 of $20.0 million, a 10% increase over $18.2 ... a constant currency basis, revenues grew 11% during the ... of 2013.  The effect of foreign currency exchange reduced ...
(Date:7/31/2014)... 31, 2014 Tandem Diabetes Care®, Inc. (NASDAQ: ... the t:slim® Insulin Pump, today reported its financial results for ... comparing the second quarter of 2014 to the same period ... million from $5.5 million , t:slim Pump shipments grew ... In comparing six months ended June 30, 2014 to the ...
Breaking Medicine Technology:Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 2Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4
... , NEW YORK, Dec. 8 ... is available in its catalogue: , South Korean ... , http://www.reportlinker.com/p0166833/South-Korean-Market-for-Dental-Implants-and-Final-Abutments-2009.html , In 2008, the ... was the largest in the Asia-Pacific region. The intense ...
... , ... that a new market research report is available in ... European Market Analysis , http://www.reportlinker.com/p0164273/Radiopharmaceuticals---A-US-and-European-Market-Analysis.html , ... heightened interest in therapeutic efficiency, acceptance and utilization of ...
Cached Medicine Technology:Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 2Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 3Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 4Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 5Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 6Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 2Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 3Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 4Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 5Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 6Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 7Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 8Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 9Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 10
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: